<DOC>
	<DOCNO>NCT01254656</DOCNO>
	<brief_summary>This study assess long-term safety efficacy lersivirine patient complete 96 week treatment lersivirine study A5271015 A5271022 .</brief_summary>
	<brief_title>A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022</brief_title>
	<detailed_description>The trial terminate prematurely January 29 , 2013 , due decision sponsor discontinue development lersivirine . The decision terminate trial base safety efficacy concern .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Patients must complete 96 week treatment lersivirine ( comparator require local regulation ) one parent protocol ( A5271015 A5271022 ) . Patients must viral load less 50 copies/mL Week 84 parent protocol . For woman child , negative urine pregnancy test Day 1 visit . Patients Grade 4 Division AIDS toxicity ( except lipid asymptomatic glucose elevation include trial . Patients treat another investigational product another clinical trial , except lersivirine parent protocol include trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>